Centessa Announces Q3 EPS of 41 Cents, Exceeding Consensus Estimate of 39 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Progress on OX2R Agonist Program: Centessa's ORX750 shows promising results as a potential best-in-class OX2R agonist for treating NT1, NT2, and IH, achieving significant outcomes in key measures during Phase 2a trials.
Safety and Efficacy: The clinical data indicates a favorable safety profile and a wide therapeutic window for ORX750, with plans to initiate a registrational program in Q1 2026.
Advancements in Other Candidates: ORX142 has demonstrated a differentiated profile in Phase 1 studies, leading to plans for patient studies starting in Q1 2026, while ORX489 is progressing through IND enabling studies.
Leadership in Neuroscience: Centessa aims to establish a strong position in the emerging class of orexin agonists, building a long-term growth platform in neuroscience with multiple candidates in development.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 38.75 USD with a low forecast of 27.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.240
Low
27.00
Averages
38.75
High
62.00
Current: 25.240
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Centessa Pharmaceuticals Presents New OX2R Agonist Data, Enhancing Mood in Depression Models
- New Data Presentation: Centessa Pharmaceuticals showcased preclinical data on OX2R agonists at the ACNP annual meeting, demonstrating significant improvements in behavioral despair and wakefulness in depression animal models, indicating potential for rapid mood enhancement.
- Clear Strategic Direction: CEO Mario Alberto Accardi, PhD, emphasized the company's commitment to exploring new therapeutic options through its multi-asset OX2R agonist pipeline, addressing mood symptoms and excessive daytime sleepiness, showcasing foresight in the neuroscience field.
- Clinical Trial Progress: The OX2R agonist ORX750 is currently undergoing Phase 2 CRYSTAL-1 study aimed at treating sleep-wake disorders, including narcolepsy, indicating Centessa's potential expansion into high unmet clinical needs.
- Solid Scientific Foundation: The presented research supports the scientific basis for OX2R agonists as novel treatment modalities, potentially offering new therapeutic options for various neuropsychiatric disorders, further solidifying Centessa's leadership in this domain.
Continue Reading
Centessa Pharmaceuticals (CNTA) Shares Hit $22.44 with RSI at 28.4, Indicating Oversold Condition
- Oversold Signal: Centessa Pharmaceuticals' RSI has dropped to 28.4, indicating that the recent heavy selling may be exhausting itself, prompting investors to consider entry points for buying, reflecting a growing market interest in the stock.
- Price Fluctuation: CNTA's stock has a 52-week low of $9.60 and a high of $30.58, with the current trading price at $22.51, suggesting potential for a rebound amidst volatility.
- Market Comparison: Compared to the S&P 500 ETF (SPY) RSI of 60.5, CNTA's low RSI may attract investors looking for undervalued stocks, highlighting a divergence in market sentiment.
- Investor Attention: The current oversold condition may lead investors to reassess CNTA's value, especially as its price approaches the 52-week low, potentially stimulating increased buying interest.
Continue Reading